Principal Investigators: Chengzu Long, PhD
Script Biosciences, an early-stage biotech company, has dedicated its efforts to the development of safe, effective, and long-lasting cures for genetic disorders that have limited or no treatment options. The company accomplishes this through its proprietary CasPlus genome editing platform, which allows for the predictable and efficient insertion of base pairs to correct mutations. The superior precision of CasPlus has paved the way towards safer genome editing in humans. The technology was initially developed at New York University, and Script Biosciences holds a worldwide license for its use.